Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 3/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29683133 | 0.76 | TGFBR1 (0.33) | RBP4KDM4ENPC1POLBRAB9A | |
| SCHEMBL446360 | 0.74 | PDE10A (0.38) | RBP4MKNK1NPC1RAB9A | |
| SCHEMBL3122117 | 0.74 | PDE4A (0.34) | RBP4MKNK1 | |
| SCHEMBL9935117 | 0.74 | RBP4 (0.32) | RBP4MKNK1 | |
| SCHEMBL11128086 | 0.74 | ALDH1A1 (0.38) | RBP4KDM4E | |
| SCHEMBL2067945 | 0.74 | PDE4A (0.32) | RBP4KDM4ENPC1RAB9A | |
| SCHEMBL5309811 | 0.74 | NPC1 (0.57) | AHRKDM4ENPC1POLBRAB9A | |
| Hydrochloric Acid SCHEMBL23290947 | 0.72 | DYRK1A (0.46) | RBP4MKNK1KDM4E | |
| SCHEMBL1743955 | 0.71 | AHR (0.44) | AHR | |
| SCHEMBL9968611 | 0.70 | PDE4A (0.33) | RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370769-B2 | TRPC5 inhibitors and methods of using same | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2022-06-28 | — | — | US | disclosed |
| CN-112239452-B | Electron transport type heteroanthracene derivative and organic electroluminescent device thereof | 武汉尚赛光电科技有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-20210078998-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| CN-112239452-A | Electron transport type heteroanthracene derivative and organic electroluminescent device thereof | 武汉尚赛光电科技有限公司 | 2021-01-19 | — | — | CN | disclosed |
| US-20200216411-A1 | TRPC5 INHIBITORS AND METHODS OF USING SAME | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2020-07-09 | — | — | US | disclosed |
| US-20130190314-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-07-25 | — | — | US | disclosed |
| US-8148524-B2 | Process for producing sulfonyl chloride compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| EP-2398802-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2011-12-28 | — | — | EP | disclosed |
| EP-2385946-A1 | DERIVATIVES OF 6-CYCLOAMINO-2,3-DI-PYRIDINYL-IMIDAZO[1,2-B]-PYRIDAZINE, PREPARATION AND TUERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2011-11-16 | — | — | EP | disclosed |
| US-8040450-B2 | Liquid crystal electro-optic device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| EP-1932846-B1 | METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010070237-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010070238-A1 | DERIVATIVES OF 6-CYCLOAMINO-2,3-DI-PYRIDINYL-IMIDAZO[1,2-B]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010034500-A1 | SUBSTITUTED IMIDAZOPYRIDINE, IMIDAZOPYRAZINE, IMIDAZOPYRIDAZINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| EP-2168965-A1 | Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-03-31 | — | — | EP | disclosed |
| US-20090247748-A1 | PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-1932846-A1 | METHOD FOR PRODUCING SULFONYL CHLORIDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247748-A1 | PROCESS FOR PRODUCING SULFONYL CHLORIDE COMPOUND | SALL4, CLCN2, CLIC1 | RBP4 718/4885AHR 1818/4885MKNK1 3848/4885 |
| US-20210078998-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | RBP4 4530/4885AHR 1728/4885MKNK1 28/4885 |
| US-20200216411-A1 | TRPC5 INHIBITORS AND METHODS OF USING SAME | TRPC5, TRPC1, TRPC7 | RBP4 3330/4885AHR 3212/4885MKNK1 1963/4885 |
| US-20130190314-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC USE THEREOF | CSNK2A1, CSNK1A1, CSNK2A2 | RBP4 3539/4885AHR 3650/4885MKNK1 200/4885 |
| US-11370769-B2 | TRPC5 inhibitors and methods of using same | TRPC5, TRPC1, TRPC7 | RBP4 3330/4885AHR 3212/4885MKNK1 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.